Investors & Media

Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

– In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed –

Read more
You are now leaving to visit